News
Public · Published
IDEXX Laboratories, Inc. (IDXX) Raises 2026 Revenue and EPS Outlook
IDEXX reported third-quarter 2026 revenue of $1.2 billion, up 10%, and diluted earnings per share of $4.01, up 18% as reported. It raised its 2026 revenue outlook to $4.7 billion–$4.8 billion and earnings-per-share outlook to $14.96–$15.16, but lowered its operating margin outlook.
Published:
Updated:
What happened
IDEXX reported third-quarter 2026 revenue of $1.2 billion, up 10%, and diluted earnings per share of $4.01, up 18% as reported. It raised its 2026 revenue outlook to $4.7 billion–$4.8 billion and earnings-per-share outlook to $14.96–$15.16, but lowered its operating margin outlook.
Confirmed
Global impact / market context
Higher guidance points to stronger expected sales and earnings, but the lower operating margin outlook signals that costs may absorb more of each revenue dollar than previously expected. If that persists, earnings growth could lag sales growth and limit how much cash the business retains.
Analyst inference
The figures present a mixed outlook: IDEXX raised revenue and earnings expectations while trimming its profitability target. The company also attributed $5 million of the revenue-guidance midpoint increase to its recent CoVet acquisition, so investors will need to distinguish acquired sales from growth elsewhere.
Analyst inference
What to watch
- Compare upcoming revenue with the $4.7 billion–$4.8 billion full-year outlook; results below that range could make the raised sales expectation harder to achieve. Analyst inference
- Track operating margin against the lowered outlook; operating margin means the share of sales remaining after operating costs, so a weaker result could indicate cost pressure. Analyst inference
- Watch whether the company delivers its $14.96–$15.16 earnings-per-share outlook, while noting third-quarter diluted EPS included $0.08 per share in specified investment, tax, and currency benefits. Analyst inference
Evidence
- Original source link unavailable